Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 27, 2026, 1:20 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 533573 | NSE: APLLTD

Alembic Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 27, 2026, 1:20 am

Market Cap 14,370 Cr.
Current Price 730
Intrinsic Value₹578.10
High / Low 1,108/725
Stock P/E21.7
Book Value 271
Dividend Yield1.51 %
ROCE13.0 %
ROE11.4 %
Face Value 2.00
PEG Ratio5.65

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Alembic Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 122 Cr. 97.2 137/84.325.3 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.69/1.60 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 3,447 Cr. 316 479/20872.1 24.30.21 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 30.2 Cr. 38.8 79.8/37.2 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 94.5 Cr. 64.5 64.7/17.0378 6.930.00 %13.5 %11.0 % 10.0
Industry Average20,667.56 Cr1,107.5056.62201.210.37%16.35%15.16%6.10

All Competitor Stocks of Alembic Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1,5091,4061,4861,5951,6311,5171,5621,6481,6931,7701,7111,9101,876
Expenses 1,2741,2031,2871,3871,3641,2571,3251,4091,4331,4981,4301,5941,585
Operating Profit 235204199208266260237239260271281316292
OPM % 16%14%13%13%16%17%15%15%15%15%16%17%16%
Other Income 01121034230101468-27
Interest 15141416151113192225242423
Depreciation 67746668696969717069747680
Profit before tax 154116130135185183157180178192190224162
Tax % 21%-31%7%-1%2%3%14%15%23%18%19%18%18%
Net Profit 122153121137180178135153138157154184132
EPS in Rs 6.207.766.146.959.189.076.857.807.047.987.859.406.76

Last Updated: February 6, 2026, 7:47 pm

Below is a detailed analysis of the quarterly data for Alembic Pharmaceuticals Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 1,876.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,910.00 Cr. (Sep 2025) to 1,876.00 Cr., marking a decrease of 34.00 Cr..
  • For Expenses, as of Dec 2025, the value is 1,585.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,594.00 Cr. (Sep 2025) to 1,585.00 Cr., marking a decrease of 9.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 292.00 Cr.. The value appears to be declining and may need further review. It has decreased from 316.00 Cr. (Sep 2025) to 292.00 Cr., marking a decrease of 24.00 Cr..
  • For OPM %, as of Dec 2025, the value is 16.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Sep 2025) to 16.00%, marking a decrease of 1.00%.
  • For Other Income, as of Dec 2025, the value is -27.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Sep 2025) to -27.00 Cr., marking a decrease of 35.00 Cr..
  • For Interest, as of Dec 2025, the value is 23.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 24.00 Cr. (Sep 2025) to 23.00 Cr., marking a decrease of 1.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 80.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Sep 2025) to 80.00 Cr., marking an increase of 4.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 162.00 Cr.. The value appears to be declining and may need further review. It has decreased from 224.00 Cr. (Sep 2025) to 162.00 Cr., marking a decrease of 62.00 Cr..
  • For Tax %, as of Dec 2025, the value is 18.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 18.00%.
  • For Net Profit, as of Dec 2025, the value is 132.00 Cr.. The value appears to be declining and may need further review. It has decreased from 184.00 Cr. (Sep 2025) to 132.00 Cr., marking a decrease of 52.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 6.76. The value appears to be declining and may need further review. It has decreased from 9.40 (Sep 2025) to 6.76, marking a decrease of 2.64.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 18, 2026, 6:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,8632,0563,1663,1053,1313,9354,6065,3935,3065,6536,2296,6727,267
Expenses 1,5061,6532,1592,4902,4883,0613,3833,9134,4324,9705,2965,6646,107
Operating Profit 3584031,0076156438741,2231,4808746829321,0081,160
OPM % 19%20%32%20%21%22%27%27%16%12%15%15%16%
Other Income 447279-398756-228562
Interest 1045531827161850567996
Depreciation 40447283105115157183287275273279299
Profit before tax 3113599365295417491,0001,368625355632707767
Tax % 24%21%23%23%22%21%20%19%17%4%3%18%
Net Profit 2362837204034135838011,146521342616582626
EPS in Rs 12.4915.0138.2021.3921.8931.0043.9758.3326.5017.4031.3329.6831.99
Dividend Payout % 24%23%9%19%18%18%23%24%38%46%35%37%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)19.92%154.42%-44.03%2.48%41.16%37.39%43.07%-54.54%-34.36%80.12%-5.52%
Change in YoY Net Profit Growth (%)0.00%134.50%-198.44%46.51%38.68%-3.77%5.68%-97.61%20.18%114.47%-85.64%

Alembic Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:12%
5 Years:8%
3 Years:8%
TTM:8%
Compounded Profit Growth
10 Years:7%
5 Years:-8%
3 Years:3%
TTM:-6%
Stock Price CAGR
10 Years:4%
5 Years:1%
3 Years:14%
1 Year:-14%
Return on Equity
10 Years:18%
5 Years:13%
3 Years:11%
Last Year:11%

Last Updated: September 4, 2025, 10:45 pm

Balance Sheet

Last Updated: December 10, 2025, 2:20 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 38383838383838393939393939
Reserves 6388471,5601,8652,1822,6813,1825,0285,1984,3314,7795,1525,280
Borrowings 109264114897081,1281,7475847177225131,2581,489
Other Liabilities 4324937186981,0139311,0221,0581,1671,0901,1141,3241,589
Total Liabilities 1,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,397
Fixed Assets 3975477087999931,1581,5521,7881,7982,3982,5472,5242,834
CWIP 2183933961,0101,5511,8462,1832,304601524837903
Investments 3287504249182361189693127129
Other Assets 7961,0091,5411,4441,8962,0192,5732,5022,9023,0873,2814,2854,531
Total Assets 1,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,397

Below is a detailed analysis of the balance sheet data for Alembic Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 39.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 39.00 Cr..
  • For Reserves, as of Sep 2025, the value is 5,280.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,152.00 Cr. (Mar 2025) to 5,280.00 Cr., marking an increase of 128.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 1,489.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,258.00 Cr. (Mar 2025) to 1,489.00 Cr., marking an increase of 231.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 1,589.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,324.00 Cr. (Mar 2025) to 1,589.00 Cr., marking an increase of 265.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 8,397.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,773.00 Cr. (Mar 2025) to 8,397.00 Cr., marking an increase of 624.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 2,834.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,524.00 Cr. (Mar 2025) to 2,834.00 Cr., marking an increase of 310.00 Cr..
  • For CWIP, as of Sep 2025, the value is 903.00 Cr.. The value appears strong and on an upward trend. It has increased from 837.00 Cr. (Mar 2025) to 903.00 Cr., marking an increase of 66.00 Cr..
  • For Investments, as of Sep 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 127.00 Cr. (Mar 2025) to 129.00 Cr., marking an increase of 2.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 4,531.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,285.00 Cr. (Mar 2025) to 4,531.00 Cr., marking an increase of 246.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 8,397.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,773.00 Cr. (Mar 2025) to 8,397.00 Cr., marking an increase of 624.00 Cr..

Notably, the Reserves (5,280.00 Cr.) exceed the Borrowings (1,489.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 2401729483293128124491,46355272480388
Cash from Investing Activity + -81-256-307-486-884-756-731-840-372-448-321-568
Cash from Financing Activity + -15187-224-12950359155-597-217-262-438444
Net Cash Flow 83417-286-69115-12726-371445-37

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow249.00139.00-113.00526.00-65.00873.000.00-583.00157.00-40.00419.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 546440406145692456686077
Inventory Days 159196266269302356417431406315350466
Days Payable 148166264213313237220194178145157179
Cash Conversion Cycle 6594429651164266261283237253363
Working Capital Days 453236616924507374778887
ROCE %44%38%66%29%22%23%24%26%11%7%13%13%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 69.61%69.61%69.61%69.61%69.61%69.61%69.61%69.61%69.67%69.68%69.74%69.74%
FIIs 4.55%4.34%4.51%4.52%4.46%4.32%3.94%4.17%3.94%3.96%4.04%4.23%
DIIs 13.32%13.65%14.22%14.51%15.39%15.47%16.05%16.05%16.43%16.46%16.30%16.17%
Public 12.53%12.39%11.67%11.36%10.54%10.61%10.38%10.17%9.96%9.91%9.92%9.84%
No. of Shareholders 99,52297,60789,55285,21276,56774,82991,42993,94491,33689,01389,96987,000

Shareholding Pattern Chart

No. of Shareholders

Alembic Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Kotak Small Cap Fund 3,427,766 1.64 268.46N/AN/AN/A
DSP Mid Cap Fund 2,122,883 0.87 166.262,129,8892025-12-15 00:56:17-0.33%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 1,523,120 1.79 119.291,443,3862026-02-20 08:10:255.52%
DSP Small Cap Fund 1,500,000 0.73 117.481,409,0912025-12-08 05:15:136.45%
Axis Small Cap Fund 1,455,416 0.45 113.99N/AN/AN/A
DSP ELSS Tax Saver Fund 1,434,898 0.65 112.381,252,6672025-12-08 05:15:1314.55%
DSP Healthcare Fund 1,428,180 3.76 111.861,423,5632025-12-08 05:15:130.32%
DSP Aggressive Hybrid Fund 810,789 0.54 63.5N/AN/AN/A
DSP Large Cap Fund 608,603 0.67 47.67N/AN/AN/A
ICICI Prudential Smallcap Fund 511,206 0.49 40.04477,1052026-02-21 21:53:207.15%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 29.6831.3317.4026.5060.81
Diluted EPS (Rs.) 29.6831.3317.4026.5060.81
Cash EPS (Rs.) 43.7445.2532.9940.8366.05
Book Value[Excl.RevalReserv]/Share (Rs.) 264.10245.14222.36266.47257.80
Book Value[Incl.RevalReserv]/Share (Rs.) 264.10245.14222.36266.47257.80
Revenue From Operations / Share (Rs.) 339.46316.90287.59269.95274.39
PBDIT / Share (Rs.) 53.4648.9336.1847.0479.75
PBIT / Share (Rs.) 39.2935.0522.1732.4570.42
PBT / Share (Rs.) 35.9432.2019.6131.5569.60
Net Profit / Share (Rs.) 29.5731.3818.9726.2356.72
NP After MI And SOA / Share (Rs.) 29.6831.3317.4026.5059.94
PBDIT Margin (%) 15.7415.4312.5817.4229.06
PBIT Margin (%) 11.5711.067.7012.0225.66
PBT Margin (%) 10.5810.156.8211.6825.36
Net Profit Margin (%) 8.719.906.599.7120.67
NP After MI And SOA Margin (%) 8.749.886.059.8121.84
Return on Networth / Equity (%) 11.2312.787.829.9422.97
Return on Capital Employeed (%) 14.4013.809.5811.7925.49
Return On Assets (%) 7.509.555.537.3117.56
Long Term Debt / Equity (X) 0.000.000.000.000.03
Total Debt / Equity (X) 0.230.080.140.120.03
Asset Turnover Ratio (%) 0.930.980.770.730.79
Current Ratio (X) 1.692.121.781.672.01
Quick Ratio (X) 0.740.980.870.720.85
Inventory Turnover Ratio (X) 3.390.890.860.780.93
Dividend Payout Ratio (NP) (%) 37.0625.5357.4752.820.00
Dividend Payout Ratio (CP) (%) 25.0817.6931.8334.060.00
Earning Retention Ratio (%) 62.9474.4742.5347.180.00
Cash Earning Retention Ratio (%) 74.9282.3168.1765.940.00
Interest Coverage Ratio (X) 13.3417.1114.1752.1597.85
Interest Coverage Ratio (Post Tax) (X) 8.2111.988.4330.0870.59
Enterprise Value (Cr.) 19368.4619611.9710301.5015131.7919003.45
EV / Net Operating Revenue (X) 2.903.151.822.853.52
EV / EBITDA (X) 18.4320.3914.4916.3712.12
MarketCap / Net Operating Revenue (X) 2.743.101.722.753.52
Retention Ratios (%) 62.9374.4642.5247.170.00
Price / BV (X) 3.524.012.232.783.70
Price / Net Operating Revenue (X) 2.743.101.722.753.52
EarningsYield 0.030.030.030.030.06

After reviewing the key financial ratios for Alembic Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
  • For Cash EPS (Rs.), as of Mar 25, the value is 43.74. This value is within the healthy range. It has decreased from 45.25 (Mar 24) to 43.74, marking a decrease of 1.51.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.10. It has increased from 245.14 (Mar 24) to 264.10, marking an increase of 18.96.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.10. It has increased from 245.14 (Mar 24) to 264.10, marking an increase of 18.96.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 339.46. It has increased from 316.90 (Mar 24) to 339.46, marking an increase of 22.56.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 53.46. This value is within the healthy range. It has increased from 48.93 (Mar 24) to 53.46, marking an increase of 4.53.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 39.29. This value is within the healthy range. It has increased from 35.05 (Mar 24) to 39.29, marking an increase of 4.24.
  • For PBT / Share (Rs.), as of Mar 25, the value is 35.94. This value is within the healthy range. It has increased from 32.20 (Mar 24) to 35.94, marking an increase of 3.74.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 29.57. This value is within the healthy range. It has decreased from 31.38 (Mar 24) to 29.57, marking a decrease of 1.81.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
  • For PBDIT Margin (%), as of Mar 25, the value is 15.74. This value is within the healthy range. It has increased from 15.43 (Mar 24) to 15.74, marking an increase of 0.31.
  • For PBIT Margin (%), as of Mar 25, the value is 11.57. This value is within the healthy range. It has increased from 11.06 (Mar 24) to 11.57, marking an increase of 0.51.
  • For PBT Margin (%), as of Mar 25, the value is 10.58. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 10.58, marking an increase of 0.43.
  • For Net Profit Margin (%), as of Mar 25, the value is 8.71. This value is within the healthy range. It has decreased from 9.90 (Mar 24) to 8.71, marking a decrease of 1.19.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.74. This value is within the healthy range. It has decreased from 9.88 (Mar 24) to 8.74, marking a decrease of 1.14.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 11.23. This value is below the healthy minimum of 15. It has decreased from 12.78 (Mar 24) to 11.23, marking a decrease of 1.55.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 14.40. This value is within the healthy range. It has increased from 13.80 (Mar 24) to 14.40, marking an increase of 0.60.
  • For Return On Assets (%), as of Mar 25, the value is 7.50. This value is within the healthy range. It has decreased from 9.55 (Mar 24) to 7.50, marking a decrease of 2.05.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.23, marking an increase of 0.15.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.93. It has decreased from 0.98 (Mar 24) to 0.93, marking a decrease of 0.05.
  • For Current Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.69, marking a decrease of 0.43.
  • For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.74, marking a decrease of 0.24.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.39. This value is below the healthy minimum of 4. It has increased from 0.89 (Mar 24) to 3.39, marking an increase of 2.50.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.06. This value is within the healthy range. It has increased from 25.53 (Mar 24) to 37.06, marking an increase of 11.53.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 25.08. This value is within the healthy range. It has increased from 17.69 (Mar 24) to 25.08, marking an increase of 7.39.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 62.94. This value is within the healthy range. It has decreased from 74.47 (Mar 24) to 62.94, marking a decrease of 11.53.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 74.92. This value exceeds the healthy maximum of 70. It has decreased from 82.31 (Mar 24) to 74.92, marking a decrease of 7.39.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 13.34. This value is within the healthy range. It has decreased from 17.11 (Mar 24) to 13.34, marking a decrease of 3.77.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.21. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 8.21, marking a decrease of 3.77.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 19,368.46. It has decreased from 19,611.97 (Mar 24) to 19,368.46, marking a decrease of 243.51.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.90. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.90, marking a decrease of 0.25.
  • For EV / EBITDA (X), as of Mar 25, the value is 18.43. This value exceeds the healthy maximum of 15. It has decreased from 20.39 (Mar 24) to 18.43, marking a decrease of 1.96.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 2.74, marking a decrease of 0.36.
  • For Retention Ratios (%), as of Mar 25, the value is 62.93. This value is within the healthy range. It has decreased from 74.46 (Mar 24) to 62.93, marking a decrease of 11.53.
  • For Price / BV (X), as of Mar 25, the value is 3.52. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 24) to 3.52, marking a decrease of 0.49.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 2.74, marking a decrease of 0.36.
  • For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Alembic Pharmaceuticals Ltd as of February 26, 2026 is: ₹544.42

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 26, 2026, Alembic Pharmaceuticals Ltd is Overvalued by 25.42% compared to the current share price ₹730.00

Intrinsic Value of Alembic Pharmaceuticals Ltd as of February 26, 2026 is: ₹565.31

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 26, 2026, Alembic Pharmaceuticals Ltd is Overvalued by 22.56% compared to the current share price ₹730.00

Last 5 Year EPS CAGR: 3.84%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 26.33%, which is a positive sign.
  2. The company has higher reserves (3,286.38 cr) compared to borrowings (726.31 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (4.08 cr) and profit (501.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 59.67, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 181.25, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alembic Pharmaceuticals Ltd:
    1. Net Profit Margin: 8.71%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 14.4% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 11.23% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 8.21
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.74
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 21.7 (Industry average Stock P/E: 56.62)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.23
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 6032.63 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAlembic Road, Vadodra Gujarat 390003Contact not found
Management
NamePosition Held
Mr. Chirayu AminChairman & CEO
Mr. Pranav AminManaging Director
Mr. Shaunak AminManaging Director
Mr. R K BahetiDirector - Finance & CFO
Mr. Jai DiwanjiIndependent Director
Mr. Ashok BaratIndependent Director
Ms. Geeta GoradiaIndependent Director
Mr. Manish KejriwalIndependent Director

FAQ

What is the intrinsic value of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd's intrinsic value (as of 26 February 2026) is ₹565.31 which is 22.56% lower the current market price of ₹730.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹14,370 Cr. market cap, FY2025-2026 high/low of ₹1,108/725, reserves of ₹5,280 Cr, and liabilities of ₹8,397 Cr.

What is the Market Cap of Alembic Pharmaceuticals Ltd?

The Market Cap of Alembic Pharmaceuticals Ltd is 14,370 Cr..

What is the current Stock Price of Alembic Pharmaceuticals Ltd as on 26 February 2026?

The current stock price of Alembic Pharmaceuticals Ltd as on 26 February 2026 is ₹730.

What is the High / Low of Alembic Pharmaceuticals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Alembic Pharmaceuticals Ltd stocks is ₹1,108/725.

What is the Stock P/E of Alembic Pharmaceuticals Ltd?

The Stock P/E of Alembic Pharmaceuticals Ltd is 21.7.

What is the Book Value of Alembic Pharmaceuticals Ltd?

The Book Value of Alembic Pharmaceuticals Ltd is 271.

What is the Dividend Yield of Alembic Pharmaceuticals Ltd?

The Dividend Yield of Alembic Pharmaceuticals Ltd is 1.51 %.

What is the ROCE of Alembic Pharmaceuticals Ltd?

The ROCE of Alembic Pharmaceuticals Ltd is 13.0 %.

What is the ROE of Alembic Pharmaceuticals Ltd?

The ROE of Alembic Pharmaceuticals Ltd is 11.4 %.

What is the Face Value of Alembic Pharmaceuticals Ltd?

The Face Value of Alembic Pharmaceuticals Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Alembic Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports